Cullen Capital Management LLC Sells 325,307 Shares of Novo Nordisk A/S $NVO

Cullen Capital Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 26.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 899,648 shares of the company’s stock after selling 325,307 shares during the quarter. Cullen Capital Management LLC’s holdings in Novo Nordisk A/S were worth $34,106,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S during the 1st quarter worth approximately $287,660,000. Maverick Capital Ltd. acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $76,444,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $27,802,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novo Nordisk A/S by 2,414.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after purchasing an additional 286,034 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Top Novo Nordisk A/S Stories

These are some of the NVO stories that stood out recently:

Novo Nordisk A/S Stock Down 0.1%

NVO stock opened at $41.60 on Tuesday. The stock has a market cap of $185.73 billion, a P/E ratio of 10.48, a PEG ratio of 1.40 and a beta of 0.70. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company’s 50 day moving average is $39.99 and its two-hundred day moving average is $43.24.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Deutsche Bank restated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. UBS Group restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $59.44.

Read Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.

Recommended Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.